Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor.
Min-Kyu KangHeon Ju LeeJoon Hyuk ChoiPublished in: Yeungnam University journal of medicine (2019)
Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare. Its features vary from subclinical elevation of serum aminotransferase to clinically apparent acute hepatitis, which is associated with immunologic reactions. Imatinib-induced hepatotoxicity with autoimmune-like features can be treated by the discontinuation of imatinib mesylate and the administration of oral steroids. Here, we report a case of late-onset imatinib-induced hepatitis with autoimmune-like features in a patient with metastatic GIST, which was improved by oral corticosteroids.
Keyphrases
- chronic myeloid leukemia
- drug induced
- high glucose
- late onset
- diabetic rats
- small cell lung cancer
- squamous cell carcinoma
- multiple sclerosis
- early onset
- case report
- endothelial cells
- computed tomography
- magnetic resonance
- liver failure
- hepatitis b virus
- diffusion weighted imaging
- mechanical ventilation
- stress induced